ATE481978T1 - Zusammensetzungen und verfahren zur behandlung von herzkrankheiten - Google Patents

Zusammensetzungen und verfahren zur behandlung von herzkrankheiten

Info

Publication number
ATE481978T1
ATE481978T1 AT06733813T AT06733813T ATE481978T1 AT E481978 T1 ATE481978 T1 AT E481978T1 AT 06733813 T AT06733813 T AT 06733813T AT 06733813 T AT06733813 T AT 06733813T AT E481978 T1 ATE481978 T1 AT E481978T1
Authority
AT
Austria
Prior art keywords
cardiac
compositions
methods
heart diseases
treating heart
Prior art date
Application number
AT06733813T
Other languages
English (en)
Inventor
Lewis Williams
Hongbing Zhang
Yan Wang
Loriane Masuoka
Stephen Doberstein
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Application granted granted Critical
Publication of ATE481978T1 publication Critical patent/ATE481978T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06733813T 2005-01-25 2006-01-25 Zusammensetzungen und verfahren zur behandlung von herzkrankheiten ATE481978T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US64652005P 2005-01-25 2005-01-25
US67508605P 2005-04-27 2005-04-27
US67585905P 2005-04-29 2005-04-29
US70147405P 2005-07-22 2005-07-22
US71649105P 2005-09-14 2005-09-14
US73981505P 2005-11-25 2005-11-25
PCT/US2006/002313 WO2006081190A2 (en) 2005-01-25 2006-01-25 Compositions and methods for treating cardiac conditions

Publications (1)

Publication Number Publication Date
ATE481978T1 true ATE481978T1 (de) 2010-10-15

Family

ID=36740983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06733813T ATE481978T1 (de) 2005-01-25 2006-01-25 Zusammensetzungen und verfahren zur behandlung von herzkrankheiten

Country Status (8)

Country Link
US (1) US8168588B2 (de)
EP (2) EP2236153A3 (de)
JP (1) JP5058822B2 (de)
AT (1) ATE481978T1 (de)
AU (1) AU2006208241B2 (de)
CA (1) CA2590338A1 (de)
DE (1) DE602006017071D1 (de)
WO (1) WO2006081190A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US8173118B2 (en) 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
AU2007233320B2 (en) 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2098244A1 (de) * 2008-03-04 2009-09-09 Medizinische Hochschule Hannover Pharmazeutische Zusammensetzungen zur Behandlung von Herzinfarkten
CN102076352B (zh) * 2008-05-02 2016-06-15 西安大略大学 与血管有关的fgf-9和它的用途
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
EP2370093A4 (de) * 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd Neuregulin und kardiale stammzellen
US20110280834A1 (en) * 2009-01-16 2011-11-17 Cedars-Sinai Medical Center Methods and compositions for cardiac tissue regeneration
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011060583A1 (zh) * 2009-11-19 2011-05-26 浙江大学 非天然的胶原样蛋白及其应用
JP2013512877A (ja) * 2009-12-02 2013-04-18 カーディオ３ バイオサイエンシーズ エス．エー． 幹細胞の刺激のための医薬組成物
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
WO2012045096A2 (en) * 2010-10-01 2012-04-05 The Trustees Of Columbia University In The City Of New York Compositions and methods of forming cardiac progenitor cells
JP2013031151A (ja) * 2011-06-20 2013-02-07 Renesas Electronics Corp 暗号通信システムおよび暗号通信方法
WO2013148121A1 (en) 2012-03-30 2013-10-03 University Of Central Florida Research Foundation, Inc. Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling
US9445897B2 (en) 2012-05-01 2016-09-20 Direct Flow Medical, Inc. Prosthetic implant delivery device with introducer catheter
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (de) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Von kardiosphären abgeleitete exosomen zur geweberegeneration
CN110946993A (zh) * 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
KR101778202B1 (ko) * 2015-06-04 2017-09-13 (주)피앤피바이오팜 안정성이 증가된 인간 섬유아세포 성장인자-2 변이체 및 이의 용도
EP3402543B1 (de) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Aus kardiosphäre stammende zellen und durch solche zellen sekretierte exosomen in der behandlung von herzversagen mit konservierter auswurffraktion
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CA3023530C (en) * 2016-05-24 2021-02-23 Arris Enterprises Llc Efficient encrypted software distribution mechanism
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3612191B1 (de) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
EP4410368A3 (de) * 2017-06-28 2024-11-27 Children's Medical Center Corporation Förderung des lungenwachstums
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (de) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center Verfahren zur therapeutischen verwendung von exosomen und y-rnas
JP7541700B2 (ja) * 2019-06-11 2024-08-29 国立大学法人京都大学 腎間質細胞の製造方法
EP4081241A4 (de) * 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. Regenerative polypeptide und verwendungen dafür
CH717226B1 (it) * 2020-07-14 2021-09-30 Contrad Swiss Sa Idrogel per applicazione topica efficace nel limitare la degenerazione di tendini e muscoli.
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
AU2022214780A1 (en) * 2021-01-26 2023-09-07 Immunis, Inc. Molecular superstructure and methods of use thereof
EP4359425B1 (de) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2-fusionspolypeptid und verwendung bei der behandlung von muskeldystrophie, sarkopenie, kachexie oder muskelverletzungen
WO2024156835A1 (en) 2023-01-27 2024-08-02 Institut National de la Santé et de la Recherche Médicale Use of amphiregulin (areg) in methods of treating vascular hyperpermeability

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0401384B1 (de) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemisch modifizierte granulocytenkolonie erregender faktor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0394827A1 (de) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US5269326A (en) 1991-10-24 1993-12-14 Georgetown University Method for transvenously accessing the pericardial space via the right auricle for medical procedures
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20040132190A1 (en) 1995-02-28 2004-07-08 The Regents Of The University Of California Gene therapy for myocardial ischemia
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
DE69735622T2 (de) 1996-08-16 2007-04-12 MCW Research Foundation, Inc., Milwaukee Knochen morphogenetisches protein und fibroblasten wachstumsfaktor enthaltende zusammensetzungen und methoden zur induzierung der kardiogenese
US6518236B1 (en) 1996-10-16 2003-02-11 Zymogenetics, Inc. FGF homologs
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
US20040215168A1 (en) 1997-04-30 2004-10-28 Beth Israel Deaconess Medical Center Kit for transvenously accessing the pericardial space via the right atrium
US6303585B1 (en) 1997-07-03 2001-10-16 Orquest, Inc. Cross-linked polysaccharide drug carrier
US6304769B1 (en) 1997-10-16 2001-10-16 The Regents Of The University Of California Magnetically directable remote guidance systems, and methods of use thereof
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
EP1053025A2 (de) 1998-02-11 2000-11-22 The Regents of the University of California Kombination einer nukleinsäure und eines vasoaktiven mittels zur verbesserten genverabreichung
EP1064356A2 (de) 1998-03-23 2001-01-03 ZymoGenetics, Inc. Herz-derivierte stammzellen
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
AU6634400A (en) 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US6815418B2 (en) 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US7214369B2 (en) * 2003-05-05 2007-05-08 Mirus Bio Corporation Devices and processes for distribution of genetic material to mammalian limb
US20040023863A1 (en) 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
BR0315155A (pt) * 2002-10-08 2005-08-16 Ares Trading Sa Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina
NZ540937A (en) * 2002-12-02 2008-06-30 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids

Also Published As

Publication number Publication date
EP1890721B1 (de) 2010-09-22
US8168588B2 (en) 2012-05-01
AU2006208241A1 (en) 2006-08-03
EP1890721A2 (de) 2008-02-27
WO2006081190A3 (en) 2008-02-21
EP2236153A2 (de) 2010-10-06
CA2590338A1 (en) 2006-08-03
US20090018061A1 (en) 2009-01-15
HK1118210A1 (en) 2009-02-06
JP2008528511A (ja) 2008-07-31
EP2236153A3 (de) 2012-08-22
AU2006208241B2 (en) 2011-08-04
DE602006017071D1 (de) 2010-11-04
JP5058822B2 (ja) 2012-10-24
WO2006081190A2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
DE602005015451D1 (de) Auf probiotischen bakterien basierende zusammensetzung und ihre verwendung zur vorbeugung und/oder behandlung von atemwegserkrankungen und/oder infektionen sowie zur verbesserung der darmtätigkeit
ATE500319T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
HRP20070189A2 (en) Use of erythropoietin
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
EP1916964A4 (de) Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
DE60128916D1 (de) Neues, physiologisch aktives peptid und dessen verwendung
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
WO2006014678A3 (en) Compositions and methods of using angiopoietin-like 4 protein
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
WO2005007648A3 (en) Biaryl piperazinyl-pyridine analogues
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
TW200510373A (en) Substituted quinolin-4-ylamine analogues
ATE494926T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EA200702523A1 (ru) Применение эритропоэтина в низкой дозировке для стимуляции эндотелиальных клеток-предшественников, а также для регенерации органов и замедления прогрессирования повреждений конечных органов
EP4430043A4 (de) Kristalline imidazo[4,5-b pyridin-verbindung, pharmazeutische zusammensetzungen und ihre verwendung zur behandlung von medizinischen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties